Harrison Zhang

Stories

AI agent team designs a lung-cancer drug in Stanford's virtual biotech

As of October 2026: Developed the Virtual Biotech's multi-agent architecture

Stanford built a drug-discovery operation with 37,000 AI agents and no lab benches. The virtual biotech analyzed 55,984 clinical trials and proposed a lung-cancer therapy that a human pharmaceutical company matched months later.

Updated Oct 11